Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of BIA 102474

Trial Profile

A phase I trial of BIA 102474

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BIA 102474 (Primary)
  • Indications Pain
  • Focus Adverse reactions; First in man

Most Recent Events

  • 17 May 2021 Results published in the Clinical Pharmacology and Therapeutics
  • 10 Mar 2016 New trial record
  • 19 Jan 2016 According to BIAL media release, as of June 2015, the French Regulatory Authorities and by the French Ethics Committee, in accordance with Good Clinical Practices, with the Declaration of Helsinki and the inherent clinical trials related legislation approved for this trial but BIAL was informed about the occurrence of an adverse effect in a volunteer on the 11th January, BIAL immediately decided to discontinue the medication to all the participants in the trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top